Aim: Parkinson's disease (PD) is a neurological disorder resulting from decreased
dopamine (DA) secretion in the brain, which reflects impaired motor function. Thus, a drug …

Parkinson's disease (PD) is a progressive and chronic neurodegenerative disease of the
central nervous system. Early treatment for PD is efficient; however, long-term systemic …

Developing new drugs to treat Parkinson's disease efficiently is challenging. Here we report
that chitosan nanoparticles (APPDNs) could serve as novel candidates for the design of anti …

Purpose. To investigate the mechanism underlying the entry of the analgesic peptide
dalargin into brain using biodegradable polybutylcyanoacrylate (PBCA) nanoparticles (NP) …

This study aimed to investigate the ability of dopamine (DA)‐loaded polyvinylpyrrolidone‐
poly (acrylic acid)(PVP/PAAc) nanogel [synthesized by gamma (γ) radiation‐induced …

As the world's population ages, the incidence of Parkinson's disease (PD), the second most
common neurological ailment, keeps increasing. It is estimated that 1% of the global …

The current pharmacological treatments for Parkinson's disease only offer symptomatic relief
to the patients and are based on the administration of levodopa and catechol-O …

The aim of this study was to characterize nanoparticles (NPs) composed of chitosan (CS)
and evaluate their potential for brain delivery of the neurotransmitter Dopamine (DA). For …

Sustained and safe delivery of dopamine across the blood brain barrier (BBB) is a major
hurdle for successful therapy in Parkinson's disease (PD), a neurodegenerative disorder …

Polybutylcyanoacrylate nanoparticles (PBCA NPs) are candidates for a drug delivery
system, which can cross the blood–brain barrier (BBB). Because little is known about their …